| Bioactivity | IONIS-FB-LRx is a specific antisense oligonucleotide (ASO) targeting complement factor B (CFB). IONIS-FB-LRx effectively reduces circulating levels of CFB. IONIS-FB-LRx can be used for geographic atrophy (GA) research[1][2]. |
| Target | Complement factor B (CFB) |
| In Vivo | IONIS-FB-Lrx is administered by subcutaneous injection every four weeks and targets CFB’s hepatic expression[2]. |
| Name | IONIS-FB-LRx |
| CAS | 2272975-74-1 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Dreismann AK, et al. Gene targeting as a therapeutic avenue in diseases mediated by the complement alternative pathway. Immunol Rev. 2022 Nov 12. [2]. Mahmoudzadeh R, et al. Emerging treatments for geographic atrophy in age-related macular degeneration. Curr Opin Ophthalmol. 2021 May 1;32(3):294-300. |